Larimar Therapeutics
LRMR
73 hedge funds and large institutions have $103M invested in Larimar Therapeutics in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 15 closing their positions.
322% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $310K
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less funds holding
Funds holding: 80 → 73 (-7)
19% less capital invested
Capital invested by funds: $127M → $103M (-$24.2M)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.53M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.82M |
| 3 |
SIM
Spark Investment Management
New York
|
+$1.32M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.1M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$946K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$12.7M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$4.36M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$3.38M |
| 4 |
JP Morgan Chase
New York
|
-$2.26M |
| 5 |
Millennium Management
New York
|
-$685K |
LRMR Hedge Fund Activity: Q2 2016 in Review
73 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2016, worth a combined $103M — down 19% from $127M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LRMR and 8 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 28 added.
The largest buyer was Balyasny Asset Management, adding an estimated $4.53M. The largest seller was Franklin Resources, exiting entirely with an estimated $12.7M sold.
- 73 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2016, down from 80 in Q1 2016.
- Funds reported $103M of Larimar Therapeutics stock for Q2 2016, down 19% quarter-over-quarter.
- 8 funds opened new Larimar Therapeutics positions in Q2 2016 and 15 closed out, a net change of -7 holders.
- The largest Larimar Therapeutics buyer in Q2 2016 was Balyasny Asset Management, an estimated $4.53M added.
- The largest Larimar Therapeutics seller in Q2 2016 was Franklin Resources, an estimated $12.7M sold.
Based on aggregated 13F filings for Q2 2016.